CrownBio neemt OcellO B.V. over om zijn dienstenaanbod op het gebied van preklinische in vitro geneesmiddelenontwikkeling uit te breiden
Overname versterkt CrownBio’s preklinische in-vitro dienstplatforms, door hoogwaardige beeldvorming en geavanceerde tumor organoïde analyses toe te voegen aan driedimensionale immuno-oncologische geneesmiddeltesten
SAN DIEGO– (BUSINESS WIRE) – Crown Bioscience (CrownBio), een JSR Life Sciences-bedrijf en leider in preklinische diensten die biofarmaceutische bedrijven helpen bij het versnellen van de ontwikkeling van nieuwe geneesmiddelen, heeft OcellO B.V. overgenomen, een particuliere contractonderzoeksorganisatie gevestigd in Nederland. Door de overname zal CrownBio zijn portfolio van in–vitro diensten uitbreiden door de expertise van OcellO op het gebied van beeldvorming met hoge inhoud te integreren naast CrownBio’s in–vitro– en in–vivo screening en immunotherapie beoordelingsdiensten. Financiële voorwaarden worden niet bekendgemaakt.
Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20210505005619/en/
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
SAN DIEGO–(BUSINESS WIRE)– Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of in vitro services, integrating OcellO’s expertise in high content imaging alongside CrownBio’s in vitro and in vivo screens and immunotherapy assessment services. Financial terms are not being disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005619/en/
“CrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process,” said Armin Spura, PhD, Chief Executive Officer of CrownBio. “This acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery.”
The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht Organoid Technology (HUB) for drug development programs. Under the terms of the agreement, Leo Price, PhD, OcellO’s Chief Executive Officer and Chief Scientific Officer, will join CrownBio as Senior Vice President, In Vitro, to lead the Company’s in vitro business in the US and Europe.
“I am delighted to join CrownBio and help grow the company’s in vitro portfolio,” said Dr. Price. “We will continue our shared heritage of innovation and dedication to customer service to serve complex needs in early-stage cancer drug development. Our combined expertise is particularly suited for disease-relevant large-scale screening, allowing our customers to evaluate multiple drug combinations in a rapid, scientifically rigorous, and cost-effective way.”
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
About OcellO B.V.
OcellO is a leading provider of compound testing services using advanced organotypic human tissue models of cancer, inflammation, and polycystic kidney disease. Automated 3D cell culture technology is combined with high content 3D imaging and analysis in a robust platform that provides scalability without compromising biological complexity. Cancer drug discovery services utilize organoids, PDX- derived tumoroids and patient tumor-derived models representing most solid tumor types and incorporating different components of the immune system.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005619/en/
Sam Brown Inc.
Crown Bioscience Inc.